Related Experiment Video
Updated: Jul 8, 2026
A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
Published on: September 23, 2014
CMTM6: a potential biomarker in non-small cell lung carcinoma
Seda Tas Ayçiçek1, Sıddıka Fındık2
1Department of Pathology, Meram State Hospital, Konya, Turkey.
Abstract:
Lung cancer is the most common cause of cancer-related deaths worldwide. With the advent of immunotherapy, programmed cell death-1 and programmed death ligand 1 (PD-L1) inhibitors have gained clinical importance, driving research into their regulatory mechanisms. CKLF-like MARVEL transmembrane domain- containing 6 (CMTM6) has been identified as a key regulator of PD-L1. In our study, we aimed to assess the prognostic significance of PD-L1 and CMTM6 expression in patients with non-small cell lung carcinoma (NSCLC). This study included 100 patients with NSCLC. CMTM6 and PD-L1 expression were evaluated using immunohistochemistry, and H-scores were calculated. A positive correlation was observed between H-PD-L1 and H-CMTM6 scores. In addition, both immunohistochemical scores were positively correlated with tumor size and grade. Both H-PD-L1 and H-CMTM6 scores of patients with adenocarcinoma were found to be lower than those of squamous carcinoma and other carcinoma types. Non-mucinous adenocarcinomas were grouped according to their predominant pattern (Group 1: lepidic pattern, Group 2: acinar and papillary pattern, Group 3: solid, micropapillary, and complex glandular/cribriform pattern). Group 3 had higher H-PD-L1 and H-CMTM6 scores than the others. Our study demonstrated a correlation between CMTM6 and PD-L1 in NSCLC and suggested that CMTM6 may serve as a potential adverse prognostic marker.
Insights
CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) and programmed death-ligand 1 (PD-L1) expression correlate in non-small cell lung cancer. High CMTM6 expression may indicate a poorer prognosis for NSCLC patients.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Immunotherapy, particularly targeting programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1), is crucial in cancer treatment.
- CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) is recognized as a key regulator of PD-L1.
Purpose of the Study:
- To investigate the prognostic significance of PD-L1 and CMTM6 expression in non-small cell lung carcinoma (NSCLC).
- To explore the correlation between CMTM6 and PD-L1 expression in NSCLC patients.
Main Methods:
- Immunohistochemistry was used to evaluate CMTM6 and PD-L1 expression in 100 NSCLC patients.
- H-scores were calculated to quantify protein expression levels.
- Patients' tumor characteristics, including size, grade, and histological subtype, were analyzed.
Main Results:
- A positive correlation was found between H-scores for PD-L1 and CMTM6.
- Both H-PD-L1 and H-CMTM6 scores positively correlated with tumor size and grade.
- Adenocarcinoma patients showed lower H-PD-L1 and H-CMTM6 scores compared to squamous cell carcinoma and other types.
- Within non-mucinous adenocarcinomas, tumors with solid, micropapillary, and complex glandular patterns (Group 3) exhibited higher H-PD-L1 and H-CMTM6 scores.
Conclusions:
- CMTM6 expression is correlated with PD-L1 expression in NSCLC.
- CMTM6 may serve as a potential adverse prognostic marker in NSCLC.
- Tumor subtype and pattern influence PD-L1 and CMTM6 expression levels.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
